oncology
Cancer care

News in brief: Pembrolizumab in previously treated mesothelioma; COX-2 disappoints in CRC; Joe Biden plans cancer research agency

Pembrolizumab shows promise in previously treated mesothelioma Patients with previously-treated advanced malignant pleural mesothelioma (MPM) may have tumour responses lasting up to a year or more following pembrolizumab therapy, a study involving Australian patients has shown. Results from a cohort of 118 patients with MPM in the phase 2 KEYNOTE-158 study showed that an objective ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic